UB Paderborn / Katalog / Suche / in CDI

Effect of upadacitinib on atopic hand eczema in patients with moderate‐to‐severe atopic dermatitis: Results from two randomized phase 3 trials

Journal of the European Academy of Dermatology and Venereology, 2023-09, Vol.37 (9), p.1863-1870

2023

Volltextzugriff (PDF)

Upadacitinib for moderate‐to‐severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristics

Journal of the European Academy of Dermatology and Venereology, 2023-09, Vol.37 (9), p.1871-1880

2023

Volltextzugriff (PDF)

Model‐Informed Development and Registration of a Once‐Daily Regimen of Extended‐Release Tofacitinib

Clinical pharmacology and therapeutics, 2017-06, Vol.101 (6), p.745-753

2017

Volltextzugriff (PDF)

Phase 1 dose-escalation study of a siRNA targeting the RTP801 gene in age-related macular degeneration patients

Eye (London), 2012-08, Vol.26 (8), p.1099-1105

2012

Volltextzugriff (PDF)

THU0192 Evaluating Pharmacokinetic Predictors of Tofacitinib Clinical Response in Rheumatoid Arthritis

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.255-255

2016

Volltextzugriff (PDF)

FRI0110 Assessment of Immunogenicity of Live Zoster Vaccination in Rheumatoid Arthritis Patients on Background Methotrexate before and after Initiating Tofacitinib or Placebo

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.468-468

2016

Volltextzugriff (PDF)

THU0185 Tofacitinib, An Oral JAK Inhibitor, in The Treatment of Rheumatoid Arthritis: Safety and Clinical and Radiographic Efficacy in Open-Label, Long-Term Extension Studies over 7 Years

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.252-252

2016

Volltextzugriff (PDF)

Therapeutic and Safety Evaluation of Combined Aqueous Extracts of Azadirachta indica and Khaya senegalensis in Chickens Experimentally Infected with Eimeria Oocysts

Journal of Parasitology Research, 2016, Vol.2016, p.4692424-9

2016

Volltextzugriff (PDF)

THU0145 Association of Mean Changes in Laboratory Safety Parameters with C-Reactive Protein at Baseline and Week 12 in Rheumatoid Arthritis Patients Treated with Tofacitinib

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.229-229

2014

Volltextzugriff (PDF)

THU0179 Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-label, Long-term Extension up to 6 Years

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.259-259

2015

Volltextzugriff (PDF)

THU0174 Analysis of Non-melanoma Skin Cancer Across the Tofacitinib Rheumatoid Arthritis Clinical Programme

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.257-257

2015

Volltextzugriff (PDF)

AB0595 Changes in serum creatinine in patients with active rheumatoid arthritis treated with TOFACITINIB (CP-690,550)

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.672-672

2013

Volltextzugriff (PDF)

Safety evaluation of Acalypha wilkesiana in albino rats and BHK-21 cell line

Comparative clinical pathology, 2016-05, Vol.25 (3), p.543-548

2016

Volltextzugriff (PDF)

Analysis of non-melanoma skin cancer across the tofacitinib rheumatoid arthritis clinical programme

Clinical and experimental rheumatology, 2017-07, Vol.35 (4), p.614

2017

Volltextzugriff (PDF)

DOP43 Long-term efficacy of tofacitinib in patients who received extended induction therapy: results of the OCTAVE open study for tofacitinib delayed responders

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S050-S052

2019

Volltextzugriff (PDF)

DOP41 Efficacy and safety of open-label treatment with tofacitinib 10 mg twice daily in patients with ulcerative colitis with clinical response, but not remission, after 52 weeks of maintenance therapy: data from the OCTAVE studies

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S049-S050

2019

Volltextzugriff (PDF)

P619 Maintenance of efficacy following tofacitinib dose reduction in patients with ulcerative colitis in stable remission

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S425-S426

2019

Volltextzugriff (PDF)

P479 Analysis of haematological changes in tofacitinib-treated patients with ulcerative colitis across Phase 3 induction and maintenance studies

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S351-S352

2019

Volltextzugriff (PDF)

DOP027 Efficacy and safety of an additional 8 weeks of tofacitinib induction therapy: Results of the OCTAVE open study for tofacitinib 8-week induction non-responders

Journal of Crohn's and colitis, 2018-01, Vol.12 (supplement_1), p.S050-S050

2018

Volltextzugriff (PDF)

P676 Correlation of lipid levels with reduction in inflammation in patients with ulcerative colitis: Data from the tofacitinib OCTAVE clinical trials

Journal of Crohn's and colitis, 2018-01, Vol.12 (supplement_1), p.S453-S454

2018

Volltextzugriff (PDF)

P512 Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib

Journal of Crohn's and colitis, 2018-01, Vol.12 (supplement_1), p.S363-S364

2018

Volltextzugriff (PDF)

DOP025 Tofacitinib for the treatment of ulcerative colitis: analysis of malignancy rates from the OCTAVE clinical programme

Journal of Crohn's and colitis, 2018-01, Vol.12 (supplement_1), p.S048-S049

2018

Volltextzugriff (PDF)

P487 Tofacitinib for the treatment of ulcerative colitis: Analysis of infection rates from the OCTAVE clinical programme

Journal of Crohn's and colitis, 2018-01, Vol.12 (supplement_1), p.S351-S352

2018

Volltextzugriff (PDF)

OP033 The effect of tofacitinib on serum lipids and cardiovascular safety in patients with ulcerative colitis: results from the tofacitinib ulcerative colitis clinical programme

Journal of Crohn's and colitis, 2018-01, Vol.12 (supplement_1), p.S023-S023

2018

Volltextzugriff (PDF)

DOP024 Tofacitinib achieves symptomatic improvement within 3 days in moderately to severely active ulcerative colitis, regardless of prior tumour necrosis factor inhibitor treatment status: results from OCTAVE induction 1 and 2

Journal of Crohn's and colitis, 2018-01, Vol.12 (supplement_1), p.S046-S048

2018

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Effect of upadacitinib on atopic hand eczema in patients with moderate‐to‐severe atopic dermatitis: Results from two randomized phase 3 trials

Upadacitinib for moderate‐to‐severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristics

Model‐Informed Development and Registration of a Once‐Daily Regimen of Extended‐Release Tofacitinib

Phase 1 dose-escalation study of a siRNA targeting the RTP801 gene in age-related macular degeneration patients

THU0192 Evaluating Pharmacokinetic Predictors of Tofacitinib Clinical Response in Rheumatoid Arthritis

FRI0110 Assessment of Immunogenicity of Live Zoster Vaccination in Rheumatoid Arthritis Patients on Background Methotrexate before and after Initiating Tofacitinib or Placebo

THU0185 Tofacitinib, An Oral JAK Inhibitor, in The Treatment of Rheumatoid Arthritis: Safety and Clinical and Radiographic Efficacy in Open-Label, Long-Term Extension Studies over 7 Years

Therapeutic and Safety Evaluation of Combined Aqueous Extracts of Azadirachta indica and Khaya senegalensis in Chickens Experimentally Infected with Eimeria Oocysts

THU0145 Association of Mean Changes in Laboratory Safety Parameters with C-Reactive Protein at Baseline and Week 12 in Rheumatoid Arthritis Patients Treated with Tofacitinib

THU0179 Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-label, Long-term Extension up to 6 Years

THU0174 Analysis of Non-melanoma Skin Cancer Across the Tofacitinib Rheumatoid Arthritis Clinical Programme

AB0595 Changes in serum creatinine in patients with active rheumatoid arthritis treated with TOFACITINIB (CP-690,550)

Safety evaluation of Acalypha wilkesiana in albino rats and BHK-21 cell line

Analysis of non-melanoma skin cancer across the tofacitinib rheumatoid arthritis clinical programme

DOP43 Long-term efficacy of tofacitinib in patients who received extended induction therapy: results of the OCTAVE open study for tofacitinib delayed responders

DOP41 Efficacy and safety of open-label treatment with tofacitinib 10 mg twice daily in patients with ulcerative colitis with clinical response, but not remission, after 52 weeks of maintenance therapy: data from the OCTAVE studies

P619 Maintenance of efficacy following tofacitinib dose reduction in patients with ulcerative colitis in stable remission

P479 Analysis of haematological changes in tofacitinib-treated patients with ulcerative colitis across Phase 3 induction and maintenance studies

DOP027 Efficacy and safety of an additional 8 weeks of tofacitinib induction therapy: Results of the OCTAVE open study for tofacitinib 8-week induction non-responders

P676 Correlation of lipid levels with reduction in inflammation in patients with ulcerative colitis: Data from the tofacitinib OCTAVE clinical trials

P512 Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib

DOP025 Tofacitinib for the treatment of ulcerative colitis: analysis of malignancy rates from the OCTAVE clinical programme

P487 Tofacitinib for the treatment of ulcerative colitis: Analysis of infection rates from the OCTAVE clinical programme

OP033 The effect of tofacitinib on serum lipids and cardiovascular safety in patients with ulcerative colitis: results from the tofacitinib ulcerative colitis clinical programme

DOP024 Tofacitinib achieves symptomatic improvement within 3 days in moderately to severely active ulcerative colitis, regardless of prior tumour necrosis factor inhibitor treatment status: results from OCTAVE induction 1 and 2

Suchergebnisse filtern